Methods for preventing, treating or suppressing an inflammatory bowel disease, particularly Crohn's Disease are disclosed. The methods include administering a pharmaceutical composition that enhances tuft cell specification. The pharmaceutical composition can comprise succinic acid or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.

Methods for preventing, treating or suppressing an inflammatory bowel disease, particularly Crohn's Disease are disclosed. The methods include administering a pharmaceutical composition that enhances tuft cell specification. The pharmaceutical composition can comprise succinic acid or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

The presently claimed invention provides a use of a composition comprising protein hydrolysate or protein hydrolysate conjugate and at least one acid as whipping agent. The invention further relates to a method for aerating a carbohydrate containing food product by adding one protein hydrolysate or at least one protein hydrolysate conjugate and at least one acid and its salts thereof. The invention also relates to the process of preparing a composition comprising at least one protein hydrolysate conjugate and at least one acid and its salts thereof.

The presently claimed invention provides a use of a composition comprising protein hydrolysate or protein hydrolysate conjugate and at least one acid as whipping agent. The invention further relates to a method for aerating a carbohydrate containing food product by adding one protein hydrolysate or at least one protein hydrolysate conjugate and at least one acid and its salts thereof. The invention also relates to the process of preparing a composition comprising at least one protein hydrolysate conjugate and at least one acid and its salts thereof.

The present invention relates to a compound of dihydrophaseic acid 3′-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the Lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling.

The present invention relates to a compound of dihydrophaseic acid 3′-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the Lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling.

The present disclosure relates to rheology modified, low foaming aqueous antimicrobial compositions. The compositions are phase stable under acidic conditions, and do not need to be rinsed from the surface to which they are applied. The present disclosure further relates to methods of use thereof.

The present disclosure relates to rheology modified, low foaming aqueous antimicrobial compositions. The compositions are phase stable under acidic conditions, and do not need to be rinsed from the surface to which they are applied. The present disclosure further relates to methods of use thereof.

A method is provided for treating pathogens with a lipid-based carrier and organic acids. More specifically the lipid carrier may have a pKa of 2.5-4.0 and/or may be acid oil, such as Acidulated Vegetable Oil. Furthermore, compositions consistent with the method are provided wherein the lipid-based carrier increases antipathogenic action of the organic acid. For example, the carrier may have a pKa that increases the antimicrobial action of the organic acid and/or an additional essential oil. The carrier may be acid oil, such as Acidulated Vegetable Oil derived from soapstocks and/or gums, but is not limited to same. The organic acid may include, but is not limited to, formic acid, acetic acid, propionic acid, butyric acid, and combinations thereof.